Evaluating aerosol administration of a candidate TB vaccine, MVA85A, as a way to induce potent local cellular immune responses and avoid anti-vector immunity
There is an urgent need for a better vaccine against TB than BCG, which confers variable protection against pulmonary TB. Heterologous prime-boost regimens with viral vector vaccines are a leading strategy for TB vaccine development. MVA85A is a viral vector candidate TB vaccine designed to boost BC...
| Main Author: | |
|---|---|
| Other Authors: | |
| Published: |
University of Oxford
2016
|
| Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.730189 |